LY518674

产品说明书

Print
Chemical Structure| 425671-29-0 同义名 : LY-674
CAS号 : 425671-29-0
货号 : A1365021
分子式 : C23H27N3O4
纯度 : 99%
分子量 : 409.478
MDL号 : MFCD11977271
存储条件：

Pure form Sealed in dry, 2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 250 mg/mL(610.53 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO
动物实验配方：
生物活性
描述 LY518674 acts as a potent, selective PPARα agonist, with an EC50 of 42 nM for human PPARα. This drug lowers triglycerides and raises HDL-C levels, making it suitable for treating atherosclerosis. The effects include not just lipid reduction in clinical settings but also improved outcomes in experimental models[1].[2].[3].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.44mL

0.49mL

0.24mL

12.21mL

2.44mL

1.22mL

24.42mL

4.88mL

2.44mL
参考文献

[1]Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72.

[2]Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73.

[3]Khera AV, et al. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2.